WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028
WuXi Biologics (HKG: 2269) announced on June 16, 2026, a comprehensive Contract Development, Research, and...
Deals
Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics
Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO)...
Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger
Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics,...
Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access
Everest Medicines (HKG: 1952) announced a strategic cooperation agreement with JD Healthcare (HKG: 6618) to...
Insilico Medicine and Bora Pharmaceuticals Forge $2.5B Strategic Alliance to Pioneer AI-Driven Drug R&D
Insilico Medicine (HKG: 3696) announced a strategic alliance with Bora Pharmaceuticals (TPE: 6472; OTCMKTS: BORAY)...
CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem
CR Pharmaceutical Commercial Group and Innovent Biologics (HKG: 1801) have signed a strategic cooperation agreement...
Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE:...
GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures
GlaxoSmithKline plc (GSK) (NYSE: GSK) has formally terminated its neurodegenerative disease research collaboration with Alector,...
Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar
Zhaoke Ophthalmology Limited (HKG: 6622) announced the acquisition of global ownership of all intellectual property,...
Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements
Sisram Medical Ltd. (HKG: 1696) announced that the company has entered into a new sublicense...
Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting...
Drug Farm Closes First Tranche of $55 Million Series D Financing to Advance First-in-Class Pipeline Across Multiple Therapeutic Areas
Drug Farm announced the closing of the first tranche of its USD 55 million Series...
Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development
Shionogi & Co., Ltd. (TYO: 4507) announced that it has entered into a joint research...
Triastek Secures Strategic Financing to Advance 3D-Printed Oral Peptide Pipeline and Build Shanghai International R&D Center
Triastek (Nanjing) Pharmaceutical Technology Co., Ltd. (“Triastek”) announced the completion of a new strategic financing...
Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) and the Indonesian Government announced a groundbreaking...
InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments
InSilico Medicine (HKG: 3696) announced an additional strategic collaboration with China Medical System Holdings Limited...
PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates
PegBio Co., Ltd. (HKG: 2565) announced the signing of a memorandum of understanding (MOU) with...
Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise
Simcere Pharmaceutical Group (HKG: 2096) announced a global drug discovery and development collaboration agreement with...
Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics
Zhejiang Conba Pharmaceutical Co., Ltd. (SHA: 600572) announced it has entered into a strategic licensing...
Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ) has...